G1 Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference
December 27, 2018 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Dec. 27, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca,...
G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib Showing Multi-Lineage Myelopreservation Benefits in 2nd-/3rd-Line Small Cell Lung Cancer
December 19, 2018 16:01 ET
|
G1 Therapeutics
Achieved both primary endpoints: statistically significant reductions in the duration and occurrence of Grade 4 neutropeniaClinically meaningful reductions in rates of granulocyte-colony stimulating...
Preliminary Results from Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival in Combination with Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer
December 04, 2018 06:55 ET
|
G1 Therapeutics
Patients on trilaciclib received more chemotherapy cycles than those in the control armTrilaciclib showed multi-lineage myelopreservation benefits when adjusting for longer duration of treatmentSafety...
G1 Therapeutics Announces Positive Myelopreservation Data from Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Trilaciclib in Combination with Chemotherapy/Tecentriq® in First-Line Small Cell Lung Cancer
November 26, 2018 16:01 ET
|
G1 Therapeutics
Second randomized, double-blind, placebo-controlled Phase 2 trial confirms multi-lineage myelopreservation benefits of trilaciclib in first-line small cell lung cancer (1L SCLC)Statistically...
G1 Therapeutics to Present Preliminary Data from Randomized Phase 2 Trial of Trilaciclib in Metastatic Triple-Negative Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
November 09, 2018 19:40 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that preliminary data from its randomized...
G1 Therapeutics Reports Third Quarter 2018 Financial Results and Corporate Update
November 07, 2018 16:01 ET
|
G1 Therapeutics
Positive data from randomized Phase 2 trilaciclib/chemotherapy trial in first-line small cell lung cancer presented at ESMO 2018 highlight myelopreservation and immune system benefits of trilaciclib ...
G1 Therapeutics to Present at Investor Conferences in November 2018
November 06, 2018 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca,...
G1 Therapeutics to Provide Third Quarter 2018 Corporate and Financial Update on November 7, 2018
October 30, 2018 06:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference...
G1 Therapeutics Presents Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin for Treatment of First-Line Small Cell Lung Cancer
October 21, 2018 08:45 ET
|
G1 Therapeutics
New data analyses highlight myelopreservation and immune system benefits of trilaciclib in combination with chemotherapyData presented at the European Society for Medical Oncology (ESMO) 2018 Congress...
G1 Therapeutics to Present Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin at European Society for Medical Oncology (ESMO) 2018 Congress
October 09, 2018 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Oct. 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that new data from its randomized Phase 2...